½ÃÀ庸°í¼­
»óǰÄÚµå
1279779

¼¼°èÀÇ °ø¸··»Áî ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Scleral Lens Market Size study & Forecast, by Type by Application, by End User and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°ø¸··»Áî´Â ¿øÃß°¢¸· µî °¢¸·¿¡ ÀÌ»óÀÌ ÀÖ´Â »ç¶÷µéÀÇ ½Ã·Â±³Á¤¿¡ ƯȭµÈ °¡½ºÅõ°ú¼º ·»ÁîÀÔ´Ï´Ù.

°¢¸· Ç¥¸éÀ» ¿ÏÀüÈ÷ µ¤±â ¶§¹®¿¡ ÀÏ¹Ý °¡½º Åõ°ú¼º ·»Á´Ù ¾ÈÁ¤¼ºÀÌ ³ôÀº °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ÀÌ ·»Áî´Â ¹æ»çÇü °¢¸· Àý°³¼ú, ½ºÆ¼ºì½º Á¸½¼ ÁõÈıº, ÀÌ½ÄÆí´ë¼÷ÁÖº´(GVHD), ¼î±×·» ÁõÈıº, È­Çй°ÁúÀ̳ª È­»ó ºÎ»óÀ» ÀÔÀº »ç¶÷µé¿¡°Ô ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¾È°ú ȯÀÚ Áõ°¡¿Í ¼¼°è¿¡¼­ °ø¸··»ÁîÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ´Â µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ´ëü ±â¼úÀÇ ÀÌ¿ë °¡´É¼ºÀº ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

°ø¸··»Áî´Â ³ë¾È, ¿ø½Ã, ³­½Ã, °¢¸·ÀÇ ¿äö, ¾È±¸ Ç¥¸é Áúȯ, ±Ù½Ã¿Í °°Àº ½Ã·Â ¹®Á¦¸¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ¿¹Ãø ±â°£ Áß ÀÌ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °ø¸··»Áî ½ÃÀåÀÌ È°¼ºÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ½Ì°¡Æ÷¸£, Çѱ¹, ÀϺ»À» Æ÷ÇÔÇÑ µ¿¾Æ½Ã¾Æ ±¹°¡µéÀº ±Ù½Ã ºóµµ°¡ °¡Àå ³ôÀ¸¸ç, National Center for Biotechnology InformationÀÇ 2019³â ±â»ç¿¡ µû¸£¸é 2050³â±îÁö ±Ù½Ã´Â ¼¼°è¿¡¼­ 49¾ï 4,900¸¸ ¸í, °íµµ ±Ù½Ã´Â 9¾ï 2,500¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±Ù½Ã À¯º´·ü Áõ°¡¿Í ±¼Àý ¹®Á¦¸¦ °³¼±Çϱâ À§ÇØ °ø¸··»Áî¿Í °°Àº ¾È°ú Á¦Ç°¿¡ ´ëÇÑ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °ø¸··»Áî ½ÃÀåÀº ¾ÕÀ¸·Î ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ±â¼úÀÇ ¹ßÀü°ú ±Ù½Ã ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª °ø¸··»ÁîÀÇ ³ôÀº ºñ¿ëÀº 2022-2029³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ °ø¸··»Áî ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ¾È°ú Áúȯ ¹× ¾È°ú °ü·Ã ºÎ»ó Áõ°¡¿Í ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ¼öÀÍ Ãø¸é¿¡¼­ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³ë·É Àα¸ ¹× ´ë»ó Àα¸ Áõ°¡, Á¦Ç° °³¹ßÀ» À§ÇÑ Á¦ÈÞ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ª È®Àå, Á¤ºÎ ±â°ü ¹× ºñ¿µ¸® ´Üü ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¼ö³â°£ ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦ µî Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ȯ°æ°ú °æÀï ±¸µµ¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇԵ˴ϴÙ.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ½º³À¼ô
  • ¼¼°è¡¤ºÎ¹®º° ½ÃÀå Ã߻ꡤ¿¹Ãø, 2019-2029³â
    • °ø¸··»Áî ½ÃÀå, Áö¿ªº°, 2019-2029³â
    • °ø¸··»Áî ½ÃÀå : À¯Çüº°, 2019-2029³â
    • °ø¸··»Áî ½ÃÀå : ¿ëµµº°, 2019-2029³â
    • °ø¸··»Áî ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2019-2029³â
  • ÁÖ¿ä µ¿Çâ
  • Ãß»ê ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • º» Á¶»çÀÇ ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • Á¶»ç ´ë»ó ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå ¿ªÇÐ

  • °ø¸··»Áî ½ÃÀåÀÇ ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • Áõ°¡ÇÏ´Â ¾È°ú ȯÀÚ ¼ö
      • ¼¼°è °¢±¹¿¡¼­ °ø¸··»ÁîÀÇ Ã¤Åà Ȯ´ë
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • ´ëü ±â¼úÀÇ ÀÌ¿ë °¡´É¼º
    • ½ÃÀå ±âȸ
      • ±â¼úÀÇ Áøº¸
      • ±Ù½Ã ÁúȯÀÇ Áõ°¡

Á¦4Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's 5 Force ¸ðµ¨ÀÇ ¹Ì·¡Àû ¾îÇÁ·ÎÄ¡(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è Àü¹®°¡º° Àü¸Á
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¸®½ºÅ© Æò°¡ : COVID-19ÀÇ ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡ ¹ÌÄ¡´Â ÀüüÀûÀÎ ¿µÇâ¿¡ °üÇÑ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå, À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå, À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå, À¯Çüº°, ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • °ø¸··»Áî ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °¢¸· ·»Áî, ¹Ý°¢¸··»Áî
    • ¹Ì´Ï°ø¸··»Áî
    • ¿ÏÀü °ø¸··»Áî

Á¦7Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå : ¿ëµµº°, ½ÇÀû, ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå, ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • °ø¸··»Áî ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ºÒ±ÔÄ¢ÇÑ °¢¸·
    • ´« Ç¥¸é Áúȯ
    • ±¼ÀýÀÌ»ó
    • ±âŸ ¿ëµµ

Á¦8Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° : ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • °ø¸··»Áî ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • º´¿ø
    • ¾È°ú Ŭ¸®´Ð
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ¼¼°èÀÇ °ø¸··»Áî ½ÃÀå : Áö¿ªº° ºÐ¼®

  • °ø¸··»Áî ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
    • ij³ª´Ù
  • À¯·´ÀÇ °ø¸··»Áî ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ø¸··»Áî ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ °ø¸··»Áî ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • ¼¼°èÀÇ ±âŸ Áö¿ª

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • ABB Optical Group
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù °³¹ß »óȲ
    • Bausch Health Companies Inc.
    • Visionary Optics
    • Essilor
    • Art Optical Contact Lens, Inc.
    • CooperVision
    • BostonSight
    • AccuLens, Inc.
    • Tru-Form Optics
    • SynergEyes

Á¦11Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ¹ë¸®µ¥À̼Ç
    • ÃâÆÇ
  • Á¶»çÀÇ Æ¯Â¡
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
KSA 23.06.12

Global Scleral Lens Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Scleral lenses are gas permeable lenses designed specifically for vision correction for those with Keratoconus and other corneal abnormalities. These lenses completely cover the corneal surface, giving them greater stability than typical gas permeable lenses. These lenses are widely used by people who have radial keratotomies, Stevens-Johnson Syndrome, Graft vs. Host Disease (GVHD), Sjogren's Syndrome, chemical or burn injuries, or who have had a radial keratotomy. The market is being driven by factors such as growing number of ophthalmic patients and increasing adoption of scleral lenses across the globe. However, availability of Alternative Techniques may hamper the market growth.

Scleral lenses are used to treat vision problems like presbyopia, hyperopia, astigmatism, uneven cornea, ocular surface disease, and myopia. Over the projection period, it is anticipated that the disease's rising prevalence would fuel the scleral lens market. According to the World Health Organization, East Asian nations including Singapore, South Korea, and Japan have the highest frequency of myopia. According to a 2019 article from the National Center for Biotechnology Information, by the year 2050, myopia and high myopia are anticipated to impact 4,949 million and 925 million individuals worldwide, respectively. The market for scleral lenses is anticipated to develop in the future due to the rising prevalence of myopia and rising spending on ophthalmic products like scleral lenses as a remedy for refractive problems. In addition, advancements in technology and rising prevelance of myopia disorder is creating lucrative growth to the market. However, the high cost of Scleral Lens stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Scleral Lens Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to rising prevelance of eye disorders, and eye related injury, and rising technological advancement. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • ABB Optical Group
  • Bausch Health Companies Inc.
  • Visionary Optics
  • Essilor Inc
  • Art Optical Contact Lens, Inc.
  • CooperVision Inc
  • BostonSight
  • AccuLens, Inc.
  • Tru-Form Optics
  • SynergEyes

Recent Developments in the Market:

  • In November 2021, CooperVision Specialty EyeCare introduced Optimized Pupil Optics (OPO) to eye care professionals (ECPs) in the US and Canada for its Onefit MED and Onefit MED+ scleral contact lenses.
  • In October 2021, Bausch Health Companies Inc. unveiled the New 28 Lens Zenlens Dx Set to address the growing need for gas-permeable lenses to cure vision problems brought on by irregularities in the cornea.

Global Scleral Lens Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Application, End User, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Typeofferings of key players. The detailed segments and sub-segment of the market are explained below.

By Type:

  • Corneo-Scleral Lenses and Semi-Scleral Lenses
  • Mini-Scleral Lenses
  • Full Scleral Lenses

By Application:

  • Irregular Cornea
  • Ocular Surface Disease
  • Refractive Error
  • Other Applications

By End User:

  • Hospitals
  • Eye Clinics
  • Other End Users

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Scleral Lens Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Scleral Lens Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Scleral Lens Market, by Application, 2019-2029 (USD Billion)
    • 1.2.4. Scleral Lens Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Scleral Lens Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Scleral Lens Market Dynamics

  • 3.1. Scleral Lens Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing Number of Ophthalmic Patients
      • 3.1.1.2. Increasing Adoption of Scleral Lenses across the Globe
    • 3.1.2. Market Challenges
      • 3.1.2.1. Availability of Alternative Techniques
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in technology
      • 3.1.3.2. Rising prevelance of myopia disorder

Chapter 4. Global Scleral Lens Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Scleral Lens Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Scleral Lens Market by Type, Performance - Potential Analysis
  • 6.3. Global Scleral Lens Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Scleral Lens Market, Sub Segment Analysis
    • 6.4.1. Corneo-Scleral Lenses and Semi-Scleral Lenses
    • 6.4.2. Mini-Scleral Lenses
    • 6.4.3. Full Scleral Lenses

Chapter 7. Global Scleral Lens Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Scleral Lens Market by Application, Performance - Potential Analysis
  • 7.3. Global Scleral Lens Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
  • 7.4. Scleral Lens Market, Sub Segment Analysis
    • 7.4.1. Irregular Cornea
    • 7.4.2. Ocular Surface Disease
    • 7.4.3. Refractive Error
    • 7.4.4. Other Applications

Chapter 8. Global Scleral Lens Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Scleral Lens Market by End User, Performance - Potential Analysis
  • 8.3. Global Scleral Lens Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 8.4. Scleral Lens Market, Sub Segment Analysis
    • 8.4.1. Hospitals
    • 8.4.2. Eye Clinics
    • 8.4.3. Other End Users

Chapter 9. Global Scleral Lens Market, Regional Analysis

  • 9.1. Scleral Lens Market, Regional Market Snapshot
  • 9.2. North America Scleral Lens Market
    • 9.2.1. U.S. Scleral Lens Market
      • 9.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Scleral Lens Market
  • 9.3. Europe Scleral Lens Market Snapshot
    • 9.3.1. U.K. Scleral Lens Market
    • 9.3.2. Germany Scleral Lens Market
    • 9.3.3. France Scleral Lens Market
    • 9.3.4. Spain Scleral Lens Market
    • 9.3.5. Italy Scleral Lens Market
    • 9.3.6. Rest of Europe Scleral Lens Market
  • 9.4. Asia-Pacific Scleral Lens Market Snapshot
    • 9.4.1. China Scleral Lens Market
    • 9.4.2. India Scleral Lens Market
    • 9.4.3. Japan Scleral Lens Market
    • 9.4.4. Australia Scleral Lens Market
    • 9.4.5. South Korea Scleral Lens Market
    • 9.4.6. Rest of Asia Pacific Scleral Lens Market
  • 9.5. Latin America Scleral Lens Market Snapshot
    • 9.5.1. Brazil Scleral Lens Market
    • 9.5.2. Mexico Scleral Lens Market
    • 9.5.3. Rest of Latin America Scleral Lens Market
  • 9.6. Rest of The World Scleral Lens Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. ABB Optical Group
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Bausch Health Companies Inc.
    • 10.2.3. Visionary Optics
    • 10.2.4. Essilor
    • 10.2.5. Art Optical Contact Lens, Inc.
    • 10.2.6. CooperVision
    • 10.2.7. BostonSight
    • 10.2.8. AccuLens, Inc.
    • 10.2.9. Tru-Form Optics
    • 10.2.10. SynergEyes

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦